OKYO
HEALTHCAREOKYO Pharma Ltd - New
$1.68+0.08 (+5.00%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving OKYO Today?
No stock-specific AI insight has been generated for OKYO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.32$3.35
$1.68
Fundamentals
Market Cap$88M
P/E Ratio—
EPS$-0.11
Dividend Yield—
Dividend / Share—
ROE-29.7%
Profit Margin—
Debt / Equity—
Trading
Volume155K
Avg Volume (10D)—
Shares Outstanding52.5M
OKYO News
20 articles- OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in MayYahoo Finance·Apr 29, 2026
- OKYO Pharma to hold Scientific Advisory Board meeting at ASCRS 2026Proactive Investors·Apr 7, 2026
- OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual MeetingGlobeNewswire Inc.·Apr 7, 2026
- OKYO Pharma Announces Chairman and Founder Acquires SharesYahoo Finance·Mar 19, 2026
- OKYO Pharma Announces Director Acquires SharesYahoo Finance·Mar 19, 2026
- OKYO Pharma Announces Chief Development Officer and Director Acquires SharesYahoo Finance·Mar 19, 2026
- OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trialProactive Investors·Mar 18, 2026
- OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal PainYahoo Finance·Mar 18, 2026
- Dow Jones sheds more than 800 points on Trump's latest tariff threatProactive Investors·Feb 23, 2026
- OKYO Pharma to present first-in-human urcosimod data at ARVO 2026Proactive Investors·Feb 23, 2026
- OKYO Abstract Selected for Presentation at Premier Global Ophthalmology CongressYahoo Finance·Feb 23, 2026
- Nasdaq posts slim gain in calm trade as Wall Street inches upProactive Investors·Feb 17, 2026
- OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal painProactive Investors·Feb 17, 2026
- OKYO Pharma prices $20M offering to fund late-stage eye drug trialProactive Investors·Feb 13, 2026
- OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary SharesYahoo Finance·Feb 13, 2026
- OKYO Pharma Announces Public Offering of Ordinary SharesYahoo Finance·Feb 12, 2026
- OKYO Pharma appoints Leerink Partners as sales agent for ATM equity offeringProactive Investors·Feb 11, 2026
- OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink PartnersYahoo Finance·Feb 11, 2026
- OKYO Pharma appoints Flavio Mantelli as chief medical officerProactive Investors·Feb 10, 2026
- OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical OfficerYahoo Finance·Feb 10, 2026
All 20 articles loaded
Price Data
Open$1.62
Previous Close$1.60
Day High$1.65
Day Low$1.59
52 Week High$3.35
52 Week Low$1.32
52-Week Range
$1.32$3.35
$1.68
Fundamentals
Market Cap$88M
P/E Ratio—
EPS$-0.11
Dividend Yield—
Dividend / Share—
ROE-29.7%
Profit Margin—
Debt / Equity—
Trading
Volume155K
Avg Volume (10D)—
Shares Outstanding52.5M
About OKYO Pharma Ltd - New
OKYO Pharma Limited, a preclinical biopharmaceutical company, is engaged in developing therapies for patients suffering from inflammatory eye diseases and eye pain in the UK. The company is headquartered in London, the United Kingdom.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—